Germany · Delayed Price · Currency is EUR AlzeCure Pharma AB Statistics
Total Valuation
FRA:AC6 has a market cap or net worth of EUR 23.55 million. The enterprise value is 18.42 million.
| Market Cap | 23.55M |
| Enterprise Value | 18.42M |
Important Dates
The next estimated earnings date is Thursday, February 26, 2026.
| Earnings Date | Feb 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 114.91M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +32.92% |
| Shares Change (QoQ) | +25.12% |
| Owned by Insiders (%) | 5.15% |
| Owned by Institutions (%) | 7.63% |
| Float | 79.17M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 5.14 |
| P/TBV Ratio | 5.14 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -5.20 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -5.91 |
Financial Position
The company has a current ratio of 4.75, with a Debt / Equity ratio of 0.06.
| Current Ratio | 4.75 |
| Quick Ratio | 4.68 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.08 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -90.86% and return on invested capital (ROIC) is -55.84%.
| Return on Equity (ROE) | -90.86% |
| Return on Assets (ROA) | -45.54% |
| Return on Invested Capital (ROIC) | -55.84% |
| Return on Capital Employed (ROCE) | -74.32% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -321,939 |
| Employee Count | 11 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, FRA:AC6 has paid 814 in taxes.
| Income Tax | 814 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +119.40% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +119.40% |
| 50-Day Moving Average | 0.18 |
| 200-Day Moving Average | 0.22 |
| Relative Strength Index (RSI) | 45.67 |
| Average Volume (20 Days) | 1,533 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -3.60M |
| Pretax Income | -3.54M |
| Net Income | -3.54M |
| EBITDA | -3.58M |
| EBIT | -3.60M |
| Earnings Per Share (EPS) | -0.04 |
Balance Sheet
The company has 5.35 million in cash and 256,428 in debt, giving a net cash position of 5.10 million.
| Cash & Cash Equivalents | 5.35M |
| Total Debt | 256,428 |
| Net Cash | 5.10M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 4.58M |
| Book Value Per Share | 0.04 |
| Working Capital | 4.44M |
Cash Flow
In the last 12 months, operating cash flow was -3.10 million and capital expenditures -11,216, giving a free cash flow of -3.12 million.
| Operating Cash Flow | -3.10M |
| Capital Expenditures | -11,216 |
| Free Cash Flow | -3.12M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FRA:AC6 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -32.92% |
| Shareholder Yield | -32.92% |
| Earnings Yield | -15.03% |
| FCF Yield | -13.23% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |